BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 13, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xolair omalizumab: Additional Phase III data

In a double-blind Phase III trial in 628 patients aged 6 to 11 years, subcutaneous Xolair reduced the number of clinically significant exacerbations at 24 weeks by 31% compared with placebo (p=0.007). Over the course of the 1-year study, Xolair patients had 43%...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >